Natasa Cmiljanovic

Natasa Cmiljanovic, Chief Scientific Officer and Founder, is a medicinal chemist and clinical scientist with more than ten years of experience in oncology drug development. She is the co-author of various scientific articles and abstracts and inventor of numerous patents. In 2007, during her PhD thesis in the Faculty of Chemistry, at the University of Basel, Switzerland, Natasa co-discovered the best-in-class dual PI3K/mTOR drug BIMIRALISIB (PQR309) together with her brother Vladimir and successfully led its early clinical development in Europe and the USA.

Natasa was the first to synthesize BIMIRALISIB, a triazine derivative, which is a highly selective, brain penetrant, and orally bioavailable. Natasa was also responsible for the early clinical development of BIMIRALISIB in solid tumors.

In 2018, Natasa co-founded Swiss Rockets, intending to create and grow a leading innovation hub for the support of biotech startup companies.